Cargando…

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis

The development of an effective oral therapeutics is an immediate need for the control and elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of 2-hydroxypropyl-β-cyclodextrin (HPCD) modified solid lipid nanoparticles (SLNs) based oral combinational cargo syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parvez, Shabi, Yadagiri, Ganesh, Gedda, Mallikarjuna Rao, Singh, Aakriti, Singh, Om Prakash, Verma, Anurag, Sundar, Shyam, Mudavath, Shyam Lal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376178/ https://www.ncbi.nlm.nih.gov/pubmed/32699361 http://dx.doi.org/10.1038/s41598-020-69276-5

Ejemplares similares

Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity
por: Parvez, Shabi, et al.
Publicado: (2020)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An in vitro and Preclinical Study
por: Gedda, Mallikarjuna Rao, et al.
Publicado: (2020)

Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
por: Mudavath, Shyam Lal, et al.
Publicado: (2014)

Sensible graphene oxide differentiates macrophages and Leishmania: a bio-nano interplay in attenuating intracellular parasite
por: Singh, Aakriti, et al.
Publicado: (2020)

Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2014)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India
por: Fakiola, Michaela, et al.
Publicado: (2019)

Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India
por: Sinha, Prabhat K., et al.
Publicado: (2011)

Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era
por: Singh, Om Prakash, et al.
Publicado: (2015)

Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: Current Status and Future Prospects
por: Singh, Om Prakash, et al.
Publicado: (2014)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Post kala-azar dermal leishmaniasis: A threat to elimination program
por: Gedda, Mallikarjuna Rao, et al.
Publicado: (2020)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
por: Wiwanitkit, Viroj
Publicado: (2012)

Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective
por: Singh, Om Prakash, et al.
Publicado: (2016)

Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination
por: Singh, Om Prakash, et al.
Publicado: (2020)

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review
por: Pokharel, Pashupati, et al.
Publicado: (2021)

Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study
por: Sundar, Shyam, et al.
Publicado: (2014)

Diagnosis of Visceral Leishmaniasis in an Elimination Setting: A Validation Study of the Diagnostic Algorithm in India
por: Cloots, Kristien, et al.
Publicado: (2022)

Cytokine Responses to Novel Antigens in an Indian Population Living in an Area Endemic for Visceral Leishmaniasis
por: Singh, Om Prakash, et al.
Publicado: (2012)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

Visceral Leishmaniasis in the Muzaffapur Demographic Surveillance Site: A Spatiotemporal Analysis
por: Hasker, Epco, et al.
Publicado: (2018)

Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani
por: Verma, Aditya, et al.
Publicado: (2017)

Visceral Leishmaniasis in Rural Bihar, India
por: Hasker, Epco, et al.
Publicado: (2012)

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
por: Jamil, Kazi M., et al.
Publicado: (2015)

The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India
por: Singh, Neeloo, et al.
Publicado: (2014)

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Leishmania Specific CD4 T Cells Release IFNγ That Limits Parasite Replication in Patients with Visceral Leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2014)

Visceral Leishmaniasis in Muzaffarpur District, Bihar, India from 1990 to 2008
por: Malaviya, Paritosh, et al.
Publicado: (2011)

Quantitative PCR in Epidemiology for Early Detection of Visceral Leishmaniasis Cases in India
por: Sudarshan, Medhavi, et al.
Publicado: (2014)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

Topical paromomycin for New World cutaneous leishmaniasis
por: Sosa, Néstor, et al.
Publicado: (2019)

Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study
por: Singh, Om Prakash, et al.
Publicado: (2021)

Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis
por: Singh, Neetu, et al.
Publicado: (2018)

Eliminating visceral leishmaniasis in South Asia: the road ahead
por: Rijal, Suman, et al.
Publicado: (2019)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Assessing insecticide susceptibility, diagnostic dose and time for the sand fly Phlebotomus argentipes, the vector of visceral leishmaniasis in India, using the CDC bottle bioassay
por: Chaubey, Rahul, et al.
Publicado: (2023)

Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India
por: Bulstra, Caroline A., et al.
Publicado: (2018)

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
por: Hailu, Asrat, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9kjnh7bk54ii4skhg0gtqmpj5j